IRVINE, Calif., Sept. 14, 2005 (PRIMEZONE) -- "The recent spate of acquisitions and agreements by biotechnology and pharmaceutical companies affirms what is becoming more and more obvious... companies must aggressively pursue new technology and products to develop and/or bring to market," stated SmallCap Sentinel analyst D.R. Clark.
"Public companies cannot stand pat with static research and development pipelines. With the aging Baby Boomer market a cash cow waiting to happen for bio and pharma companies, now is the time to load up the shelves," Clark added. "Woe be the bio or pharma company that doesn't aggressively target technology in pharmaceuticals, stem cell research, medical devices, and more. They could well be on the outside looking in."
"Yesterday's news from Biophan Technologies, Inc. (OTCBB:BIPH) exemplifies this strategy with the company executing an agreement with MYOTECH, LLC to secure the exclusive sales and distribution rights to the MYOTECH MYO-VAD(tm) cardiac assist technology," Clark stated. "Biophan is looking to broaden its reach and scope with the rights they've secured with MYOTECH, a company that Biophan feels has 'breakthrough' technology."
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI.
The informational report "Innovations in Biotechnology" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will detail various issues affecting the current market for biotechnology companies including Baxter International Inc. (NYSE:BAX), Intuitive Surgical Inc. (Nasdaq:ISRG), ev3, Inc. (Nasdaq:EVVV) and Biophan.
Additional information regarding Biophan is available at:
http://trilogy-capital.com/biph_summary.aspx
Individuals may also register for future reports at:
http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by Biophan for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.